- Conditions
- Lymphoma
- Interventions
- autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy
- Drug · Procedure
- Lead sponsor
- Favrille
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Beverly Hills, California • Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,368
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- Fluticasone Furoate, Fluticasone Propionate, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
- Conditions
- Heroin Dependence
- Interventions
- Intranasal challenge drug
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation
- Procedure · Biological · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Obesity
- Interventions
- Low calorie high fat/protein diet
- Behavioral
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Aging, Inflammation
- Interventions
- LLP-01, Placebo
- Dietary Supplement · Other
- Lead sponsor
- LL Prosper Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Gut -Microbiota, Inflammation Biomarkers, Pain Assessment, Joint Pain
- Interventions
- Wild blueberry, Placebo
- Dietary Supplement
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Pulmonary Hypertension Associated With Interstitial Lung Disease
- Interventions
- Placebo, Seralutinib, Generic Dry Powder Inhaler
- Drug · Device
- Lead sponsor
- GB002, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Fresno, California • Albuquerque, New Mexico • Richmond, Virginia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- idarubicin, cytarabine, bortezomib, etoposide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 72 more
- Conditions
- Feeding Disorders, Specific Phobia
- Interventions
- Behavioral Intervention, d-cycloserine (DCS), Placebo
- Behavioral · Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Meniscectomy, Osteoarthritis
- Interventions
- NUsurface® Meniscus Implant, NSAID's and Non-surgical Treatment Options, Intra-Articular Injections with Corticosteroids, Intra-Articular Injections with Hyaluronic Acid (HA)
- Device · Drug
- Lead sponsor
- Phoenix Kinetics
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts • Roxbury Crossing, Massachusetts + 6 more
- Conditions
- Triple Negative Breast Cancer, Breast Cancer
- Interventions
- Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 7
- States / cities
- Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 3 more
- Conditions
- Obesity
- Interventions
- Intervention Control, Counselling, Contrave, Contrave and Counseling
- Behavioral · Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Scottsbluff, Nebraska
- Conditions
- Diet Habit, Sugar-Sweetened Beverages
- Interventions
- iSIPsmarter, Patient Education (PE)
- Behavioral
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Myeloma
- Interventions
- Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular, Psychological Stress
- Interventions
- High Antioxidant Spice Blend, Trier Psychological Stressor, Placebo antioxidant concentrate
- Dietary Supplement · Behavioral · Other
- Lead sponsor
- Penn State University
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- University Park, Pennsylvania
- Conditions
- Postprandial Hyperglycemia
- Interventions
- Resistant Starch
- Dietary Supplement
- Lead sponsor
- Kansas State University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Manhattan, Kansas
- Conditions
- Migraine Headache
- Interventions
- NPS 1776 (800 mg), PLACEBO, NPS 1776 (400 mg)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Little Rock, Arkansas • Oceanside, California + 19 more
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
- Drug · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Autism Spectrum Disorder
- Interventions
- Dark Chocolate
- Dietary Supplement
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Insulin Sensitivity, 24-hour Glucose Control
- Interventions
- HIgh UPF controlled diet, No UPF controlled diet
- Other
- Lead sponsor
- Virginia Polytechnic Institute and State University
- Other
- Eligibility
- 40 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Blacksburg, Virginia
- Conditions
- Sarcoma
- Interventions
- cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, vincristine sulfate, surgical procedure, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Mild Cognitive Impairment
- Interventions
- Grape Powder, Placebo Powder
- Dietary Supplement
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lymphoma
- Interventions
- aldesleukin, filgrastim, recombinant interferon gamma, carmustine, cyclosporine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more